Alzinova (ALZ) DNB Carnegie Småbolagsdag summary

Market overview and unmet needs

• Over 50 million people globally live with Alzheimer's, expected to double in 25 years, creating a rapidly growing market with 8–12% annual growth.

• Current treatments are costly and require frequent administration, with annual administration costs around $15,000, excluding drug costs.

• New diagnostic methods and disease-modifying drugs are expanding the market, with a single effective drug potentially reaching $12 billion in annual sales.

Pipeline and innovation

• The company is developing a therapeutic vaccine (ALZ101) entering phase 2 and an antibody (ALZ201) in preclinical stage, both targeting amyloid beta 42 oligomers.

• Their approach stabilizes toxic oligomers, aiming for a first-in-class, disease-modifying therapy distinct from current plaque-focused drugs.

• The vaccine requires only three injections per year, potentially reducing annual treatment costs to $300 and improving patient compliance.

Clinical results and scientific findings

• Phase 1B study showed robust, long-lasting immune responses in over 95% of patients, with only mild injection site reactions.

• Patients on active treatment maintained cognitive function, supported by positive trends in composite cognitive scales and relevant biomarkers.

• The vaccine restored natural antibody levels in patients to those seen in healthy elderly, suggesting a potential immunodeficiency in Alzheimer's.

• No serious amyloid-related imaging abnormalities were observed, a common issue with other drugs.